AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Carasent

M&A Activity Apr 16, 2024

3568_rns_2024-04-16_a2d52b51-cd4e-47ef-8b32-04b06ebe8148.html

M&A Activity

Open in Viewer

Opens in native device viewer

Carasent group signs contract to supply Medrave M4 to VGR

Carasent group signs contract to supply Medrave M4 to VGR

Västra Götalands Regionen and Medrave AB have today entered into an agreement

to implement Medrave to the EHR system Millennium. The annual recurring

revenue from the contract is NOK 11 million, where NOK 6 million is new

revenue.

Västra Götalands Regionen (VGR) is changing EHR system and has in connection

with this change held a tender for a system for operational monitoring and

automatic reporting to quality registries. Medrave won the tender for a 6

years agreement to provide Medrave M4. This is partly replacing the agreement

Medrave has to supply Medrave M4 to the old EHR system.

The yearly value of the contract after the implementation process is NOK 11

million with an addition of NOK 2 million of consultancy revenue the first

year. VGR is also buying Medrave for the old EHR system and as long as they

continue to do so the NOK 4-5 million VGR is paying for that solution will be

subtracted. The new income will start once the implementation is complete

which is expected in November 2024.

Carasent CEO Daniel Öhman comments:

* We are very glad that VGR wants to continue and increase the collaboration

with Medrave. It is an unrivaled system when it comes to follow-up of

primary care quality and automatic reporting to quality registries.

* In a short period of time we have now signed the two largest customer

contracts in Carasent's history. Signed but not implemented ARR is now

approximately NOK 14 million (NOK 6 million from the new VGR agreement) up

from NOK 2 million Q1 2023. Revenue growth is the key to drive our profit

margins given that we aim to keep the cost base flat, and this new ARR will

contribute significantly, as our gross margins are over 80%.

About Medrave Software AB

Founded in 1996, Medrave Software AB is a distinguished leader in healthcare

business intelligence solutions. Acquired by the Carasent Group in December

2021, Medrave offers an unparalleled BI platform, meticulously designed in

close collaboration with medical professionals. As Sweden's premier solution

for accessing and visualizing patient record data, Medrave significantly

enhances operational workflows and the quality of care. It is currently used

by more than 90% of the primary healthcare centres and 1,000 outpatient

clinics across Sweden.

For further details please contact:

Daniel Öhman, CEO Tel: +46 70-855 37 07, or

Svein Martin Bjørnstad, CFO Tel: +47 979 69 493

Talk to a Data Expert

Have a question? We'll get back to you promptly.